Navigation Links
Distinguishing friend from foe in the battle against cancer

ctive Hunter and Verma labs moved those mouse studies to the next level by tinkering with TSC activity in human cancer cells. Says Ghosh, "We were able to extend this model based on TSC null cells to different human cancer cell lines, where we knocked down TSC expression and showed that the same pattern held true."

Specifically, the team found that human cells lacking TSC genes were vulnerable to chemotherapeutic attack because they couldn't activate a major line of defense mediated by the Nuclear Factor kappa B, known as NF-kB, which triggers both inflammatory and survival responses by inducing transcription of specific genes.

Not only did this explain why TSC null cells are vulnerable to insult, but it also provided biochemical evidence that there is crosstalk between two survival mechanisms. Explains Tergaonkar, who is now an assistant professor at the Institute for Molecular and Cell Biology (IMCB) in Singapore, "Our findings show for the first time that the TSC complex can regulate the NF-kB signaling cascade."

The experiments also explained a paradox: TSC null cells treated with rapamycin actually survived cellular insult better than untreated cells-a highly inauspicious outcome if the goal is to kill cancer cells. The Hunter and Verma team found that rapamycin did that by increasing NF-kB activity in the TSC null cells when they were exposed to chemotherapeutic drugs.

Rapamycin, an immunosuppressant used to block organ rejection after transplants, also inactivates proteins stimulating cell division and in clinical trials has been combined with other drugs to halt cancer cell growth.

But to cancer cells, rapamycin is both friend and foe. "Rapamycin is not as successful as initially expected in treating cancer," explains Ghosh. "Instead of killing cells, you end up triggering a survival response in them." This study, however, suggests that taking NF-kB out of the game would make rapamycin less "friendly."

"A maj
'"/>

Source:Salk Institute


Page: 1 2 3

Related biology news :

1. W.M. Keck Foundation funds study of friendly microbes
2. Plants respond similarly to signals from friends, enemies
3. Grass makes environmentally friendly biofuel
4. Plant pathologists evaluate eco-friendly alternatives to methyl bromide
5. FDA approves child-friendly AIDS medicine
6. Mans best friend: Study shows lonely seniors prefer playtime with pooch over human interaction
7. Eco-friendly bug sucker
8. Surprising symbiosis: Glassy-winged sharpshooter eats with friends
9. Train your brain to hear your friends at a party
10. Mans best friend lends insight into human evolution
11. UN environmental agency steps up battle against marine pollution
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Distinguishing friend from foe the battle against cancer

(Date:2/18/2015)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. , Cowen and ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern Time ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern ... webcasts for these events, please visit Cepheid,s website at ...
(Date:2/12/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED METHOD AND SYSTEM TO IMPROVE ... further establishes NXT-ID,s position in the emerging "Internet of ... ability for multiple devices to collaborate with one another ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Planck Institute for Human Cognitive and Brain Sciences and ... now developed a mathematical model which could significantly improve ... the future, this kind of algorithms which imitate brain ... them. Many people will have personal experience of ...
... cells for replication and production of virus progeny. Thus ... induces therapy resistance. New improved therapies attempt to targets ... The team led by Professor Dr. Ralf Bartenschlager, ... Hygiene Institute of Heidelberg University Hospital, has identified a ...
... at Carnegie Mellon University have developed an analytical technique ... complex disease syndromes such as diabetes, asthma and cancer, ... , Rather than searching one at a time for ... as in most conventional approaches, the Carnegie Mellon ...
Cached Biology News:Doing what the brain does -- how computers learn to listen 2Doing what the brain does -- how computers learn to listen 3New strategy for inhibiting virus replication 2Carnegie Mellon develops innovative method to detect genetic causes of complex diseases 2
(Date:2/26/2015)... Los Angeles, CA (PRWEB) February 26, 2015 ... organizing an online demonstration to support life extension technologies ... to 8pm UTC, Universal Coordinated Time, on March 21st ... around the world. , Eric Schulke, Founder of ... we must act with urgency. The Movement for Indefinite ...
(Date:2/26/2015)... BioEnterprise today announced that Northeast Ohio ... in growth funding during the past 13 years.  Funding ... – including the Ohio Third Frontier - and federal ... raised in the past five years. ... BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
(Date:2/26/2015)... February 26, 2015 RURO, Inc., a ... FreezerPro® version 6.2 – the latest update to the ... is that of a quick and easy method to ... the latest version, RURO engineering has enhanced the system’s ... move large amounts of sample records. , "FreezerPro ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015 ... Gold Partner status in Oracle PartnerNetwork. In attaining Gold ... its commitment to establish Oracle-related knowledge in delivering Ceres, ... challenges of joint customers. Originally developed for ... to rapidly zoom in and out of massive amounts ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4RURO Releases FreezerPro® version 6.2 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
... Oct. 25 Cellectis (Alternext: ALCLS), the French genome ... and Application (CiRA) of Kyoto University, Kyoto, Japan, have ... to combine Cellectis, genome engineering technologies with CiRA,s induced ... characteristics of iPS cells for use as cellular tools. ...
... Oct. 22 Trius Therapeutics, Inc. (Nasdaq: TSRX ... at Trius Therapeutics, will present "Innovative Antibacterial Drugs by Design; ... event taking place on October 26, 2010 from 5:30-9:30 p.m. ... available at http://sdbn.org/october . About ...
... Bacterin International Holdings, Inc. (OTC Bulletin Board: ... for medical applications and revolutionary bone graft material, today ... M. Wickwire, a distinguished Washington, D.C. based attorney and ... & Carparelli, to its Board of Directors.  Effective immediately, ...
Cached Biology Technology:Cellectis and the Center for iPS Cells Research and Application Enter Collaboration 2Cellectis and the Center for iPS Cells Research and Application Enter Collaboration 3Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals 2Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals 3Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals 4
... targets including proteins and to their modification ... antigens. A&Gs service is divided into ... 40 days (duration may vary slightly dependent ... I: Immunization, test bleed and fusion; $2,500 ...
... Clone/PAD: ZMD.368. Immunogen: Synthetic peptide ... the human WNT2B/WNT13 protein. Specificity: ... mouse and rat WNT2B/WNT13 proteins. Recognizes ... Reactivity: Mouse Human Rat (positive ...
... Immunogen: Synthetic peptide derived from ... protein (chromosome 17 open reading frame 37 ... for the C35 protein. On Western blots ... kDa band. Reactivity: Human (positive control: ...
...
Biology Products: